NICE has published a draft of the revised clinical guideline Management of multiple sclerosis in primary and secondary care and has invited comments from registered stakeholders.
A letter to The Telegraph today suggests that more than half of people with MS in the UK may not be getting access to treatments they need.
A free app (SymTrac) that enables people to track their MS over time was launched yesterday.
The Scottish Medicines Consortium (SMC) has approved dimethyl fumarate (BG-12, Tecfidera) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland.
The MS Trust welcomes the decision by SMC.
Brain volume loss and progression of the condition were both slowed and quality of life was improved
140 people with secondary progressive multiple sclerosis took either high dose simvastatin (80mg/day) or placebo in this two year, phase II clinical trial. MRI scans measured brain volume during the course of the study, disability was measured using the EDSS scale and participants completed questionnaires to measure the impact of MS on day-to-day living. Simvastatin was well tolerated by the participants.
Research in Sweden suggests the risk of a relative of someone with MS also getting the condition is lower than previously thought.
A study at Kings College Hospital in London has found that people with MS of Caribbean descent had more rapid progression than white people.
As winter approaches, advice has been published about remaining healthy and warm during the cold weather.
Research published in the journal Nature Genetics has identified 48 new genes that may play a part in susceptibility to MS.
There are now 2.3 million people with MS around the world according to a report that accompanies the new edition of the Atlas of MS published by the Multiple Sclerosis International Federation (MSIF).